The findings from in vitro studies of PCa and breast cancer cells and in vivo studies of lung cancer support the further development of the RARγ antagonist AGN205728 and/or the pan-RAR antagonist AGN194310 for use to treat these cancers. Here, RARA is linked to lung cancer.